Patents Represented by Attorney, Agent or Law Firm Dianne Pecoraro
-
Patent number: 6028201Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: February 25, 1998Date of Patent: February 22, 2000Assignee: Merck & Co., Inc.Inventors: Christopher J. Dinsmore, George D. Hartman
-
Patent number: 6015817Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: December 4, 1997Date of Patent: January 18, 2000Assignee: Merck & Co., Inc.Inventors: Wasyl Halczenko, Craig A. Stump
-
Patent number: 6001835Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: March 25, 1997Date of Patent: December 14, 1999Assignee: Merck & Co., Inc.Inventors: Christopher J. Dinsmore, Theresa M. Williams
-
Patent number: 5998407Abstract: The present invention is directed to substituted benozdiazepine compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: October 1, 1998Date of Patent: December 7, 1999Assignee: Merck & Co., Inc.Inventors: Samuel L. Graham, John S. Wai, Neville J. Anthony
-
Patent number: 5994412Abstract: A compound represented by the formula I is disclosed: ##STR1## or a pharmaceutically acceptable salt or hydrate thereof. The compound has inhibitory activity against the oncoprotein Raf.Also included are pharmaceutical compositions, methods of treating cancer, cultures of the producing fungal microorganism and methods of fermentative production of the compound.Type: GrantFiled: July 2, 1998Date of Patent: November 30, 1999Assignee: Merck & Co., Inc.Inventors: Seok H. Lee, Maria T. Diez, Fernando Pelaez, Marina Mojena Sanchez, M. Dolores Vilella Amils, Hans E. Huber, Denis R. Patrick, Otto D. Hensens, Rosalind G. Jenkins, Leeyuan Huang, Annie Z. Zhao, Deborah L. Zink, Anne Dombrowski, Gerald F. Bills
-
Patent number: 5981562Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: January 21, 1997Date of Patent: November 9, 1999Assignee: Merck & Co., Inc.Inventors: Christopher J. Dinsmore, George D. Hartman
-
Patent number: 5977134Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: December 4, 1997Date of Patent: November 2, 1999Assignee: Merck & Co., Inc.Inventors: Terrence M. Ciccarone, Wasyl Halczenko, John H. Hutchinson, William C. Lumma, Jr., Gerald E. Stokker, Craig A. Stump, Theresa M. Williams
-
Patent number: 5972984Abstract: The present invention comprises low molecular weight peptidyl compounds that inhibit the farnesyl-protein transferase. Furthermore, these compounds differ from the mono- or dipeptidyl analogs previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.Type: GrantFiled: October 29, 1997Date of Patent: October 26, 1999Assignee: Merck & Co., Inc.Inventors: Neville J. Anthony, Jeffrey M. Bergman, S. Jane deSolms, Chrisopher J. Dinsmore, Robert P. Gomez, Suzanne C. MacTough, Kelly M. Solinsky, Theresa M. Williams
-
Patent number: 5972966Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherpeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: December 4, 1997Date of Patent: October 26, 1999Assignee: Merck & Co., Inc.Inventor: S. Jane deSolms
-
Patent number: 5968965Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: January 21, 1997Date of Patent: October 19, 1999Assignee: Merck & Co., Inc.Inventors: Christopher J. Dinsmore, George D. Hartman
-
Patent number: 5968461Abstract: The present invention relates to a process for cleaning mercury-contaminated soils that is simple, efficient and safe to use. This process can also be used to clean soils contaminated with additional metals, such as zinc, copper and lead, at a lower pH. The present invention involves screening the contaminated soil to remove unwanted materials, leaching the contaminated soils with hypochlorite in a screw reactor, thickening, leaching with hypochlorite and sodium chloride, thickening again and then separating the mercury-containing liquids from the clean soil. This invention also relates to a process which uses sulfide to treat the mercury-containing liquids.Type: GrantFiled: September 14, 1998Date of Patent: October 19, 1999Assignee: Merck & Co., Inc.Inventors: Youssef El-Shoubary, William F. Lavosky, Subash C. Seth, Ned A. Speizer
-
Patent number: 5965578Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: March 25, 1997Date of Patent: October 12, 1999Assignee: Merck & Co., Inc.Inventors: Samuel L. Graham, Theresa M. Williams, John S. Wai
-
Patent number: 5945070Abstract: A filter tube for a reaction or other fluid vessel is disclosed which maintains the vessel under an inert gas atmosphere and maintains the integrity of the inert gas seal while performing filtered or unfiltered filling or filtered draining operations.Type: GrantFiled: October 21, 1997Date of Patent: August 31, 1999Assignee: Merck & Co., Inc.Inventors: Gary S. Kath, Gregory W. King
-
Patent number: 5932590Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: December 4, 1997Date of Patent: August 3, 1999Assignee: Merck & Co., Inc.Inventors: Terrence M. Ciccarone, S. Jane deSolms
-
Patent number: 5922883Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: March 26, 1997Date of Patent: July 13, 1999Assignee: Merck & Co., Inc.Inventor: John H. Hutchinson
-
Patent number: 5914341Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: January 29, 1998Date of Patent: June 22, 1999Assignee: Merck & Co., Inc.Inventors: Christopher J. Dinsmore, George D. Hartman
-
Patent number: 5882601Abstract: An access port for a reaction or other fluid vessel which maintains the vessel under an inert gas atmosphere and maintains the integrity of the inert gas seal while performing filtered filling or draining operations is presented. The port uses a deflected septum sealing technique. The invention can be used for a number of laboratory and clinical operations on a variety of size and shape vessels. The combination of the appropriate vessel with this access port is very well suited for use in lab automation systems, such as automated solid phase chemical synthesis, biological screening, combinatorial chemistry and other areas where reaction chemistry is conducted.Type: GrantFiled: June 18, 1997Date of Patent: March 16, 1999Assignee: Merck & Co., Ltd.Inventors: Gary S. Kath, Lihu Yang, Gregory W. King
-
Patent number: 5872135Abstract: The present invention comprises analogs of the CAAX motif of the protein Ras that is modified by farnesylation in vivo. These CAAX analogs inhibit farnesyl-protein transferase. Furthermore, these CAAX analogues differ from those previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.Type: GrantFiled: March 26, 1997Date of Patent: February 16, 1999Assignee: Merk & Co., Inc.Inventor: S. Jane deSolms
-
Patent number: 5852010Abstract: The present invention is directed to substituted benozdiazepine compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: March 25, 1997Date of Patent: December 22, 1998Assignee: Merck & Co., Inc.Inventors: Samuel L. Graham, Neville J. Anthony, John S. Wai
-
Patent number: 5783398Abstract: This application describes a high throughput assay for screening for compounds capable of binding to a fusion protein which consists of a target protein and an FK506-binding protein. The method for preparing the DNA encoding for the fusion protein and for expressing that DNA is also described in the application. The invention also discloses the recombinant DNA and protein sequences for several fusion proteins.Type: GrantFiled: September 4, 1996Date of Patent: July 21, 1998Assignee: Merck & Co., Inc.Inventors: Alice Marcy, Scott P. Salowe, Douglas Wisniewski